UnitedHealth Group (UNH)

Total return at 5 years: 8.8%/year = 6.3% appreciation + 2.5% dividend. The target price ($514) is ex-dividend; the $54 in dividends collected over 5 years are added separately.

By both methods, the value today (DCF $574 · Multiples $460) exceeds the market price ($379).

Today — fairly valued: at $379 trades ~17.6% below its value discounted to today (~$460); the discount is positive but does not reach the margin of safety we require (≥38%).

At 5 years — En valor: the target price ($514) plus dividends yield between the 4% floor and the 10% average return — a reasonable return, though without the margin of a great investment.

The bridge: the return at 5 years exceeds the risk-free rate (4.5%) — but the discount does not reach the required margin of safety (≥38%). To require a 15% annual return, it would need to be bought at ~$291.

Educational / informational. Does not constitute investment advice.

The inverse approach: instead of projecting growth to obtain the value, the market price ($379) is taken as given and it solves for what annual owner-earnings growth would need to hold for 5 years for the present value —at the method's rate (4.5%, no-growth terminal)— to equal that price. It is the disconfirmation test: the expectations the price already pays for, contrasted against the method's projection.

The market discounts less growth (-3.2%/year) than we project (6.0%/year) → if the base case holds, there is margin: perception is more pessimistic than the estimated reality.

That growth implies ~$15.2 bn of owner earnings in year 5 (vs ~$23.9 bn of our base case). It recalculates if the DCF assumptions are edited.

Year-by-year projection of the selected scenario. From each year, two versions of the flow are derived: growth FCF (operating flow − total capex, the cash surplus) and maintenance FCF (the owner earnings: what the business yields if it only sustains its capacity). The flow is returned almost in full (dividend + buyback) or redeployed into the operation, so that EV stays roughly flat and multiples compress because the metric grows, not because of cash accumulation. The valuation is done on Utilidad ajustada (P/E normalizado). In edit mode, revenue, margins, capex, and exit multiples can be adjusted.

Rolling grid: year 0 is the TTM at Jun-2026 built by levels using the adjusted earnings the company reports — $16.944bn = 2025 ($14.897bn) + first half of 2026 ($12.370bn) − first half of 2025 ($10.323bn), per the non-GAAP reconciliations in the 4Q25 and 2Q26 releases. GAAP earnings for the same window are $14.122bn: the difference is the amortization of acquisition-related intangibles and restructuring and divestiture charges, net of tax. The entire path uses that same adjusted definition. That level is normalized: the window includes $1,070M pre-tax of favorable prior-year medical reserve development ($140M for all of 2025 + $1,250M for the first half of 2026 − $320M for the first half of 2025; 10-K and 2Q26 10-Q), which is subtracted at the rate guided for 2026 (18.5%), leaving the normalized year 0 at $16.072bn. The adjustment may be somewhat severe, because the company also recorded favorable development in 2023 ($840M) and 2024 ($700M); there is no published figure for a normal level, so the full amount is subtracted. UnitedHealth is managed health insurance (UnitedHealthcare + Optum): it is valued on P/E over normalized adjusted earnings, because 2025 was a trough — the medical care ratio jumped from 85.5% to 89.1% on the Medicare Advantage cost shock and operating income fell 41%. 2Q26 confirms the reversal: medical care ratio 86.7% against 89.4% a year earlier and UnitedHealthcare operating margin 4.6% against 2.4%. Path against the Jul-16-2026 guidance: guided 2026 adjusted earnings per share is $19.50-20.00 and the reported first half is $13.61, so the implied second half is $5.89-6.39. The +1yr window (Jul-2026 to Jun-2027) is that second half plus the first half of 2027: the base case ($19.59 per share) takes the midpoint of the range and a first half of 2027 ~1% below that of 2026, which does not repeat the favorable reserve development; the adverse case ($17.54) takes the low end and a ~14% decline; the favorable case ($20.75), the high end and a ~5% increase. The +1yr operating income starts from the 2026 guided floor (more than $25,450M, with $16,981M already reported for the half) with those same assumptions for the first half of 2027. Revenue guidance is a floor (more than $439,000M for 2026, set in January; the July deck does not update it) and the path respects it. The +1yr revenue window grows 1.2%, the pace of the first half of 2026 against the first half of 2025 ($223,753M against $221,191M, 10-Q), and from that floor reaccelerates toward 6.4% by year five (rebound exception); earnings for each year do not change, so the implied adjusted net margin rises to 4.6% by year five, still below the 6.3% of 2023 ($23.6bn on $371.6bn). The path recovers adjusted earnings toward ~$26.6bn (~$30 per share) by year five, with the medical care ratio normalizing toward ~85.5% (still above the 83.2% of 2023, on funding pressure: the 2027 Medicare Advantage Final Notice moved closer to the expected cost trend, but remains below it). Normalized earnings × 17× P/E (adverse 14× / favorable 19×): the managed health insurance band, discounted for the medical care ratio cycle and regulatory risk (the Department of Justice lawsuit over risk adjustment remains unresolved). P/E delivers equity directly; net debt (~$41.9bn at Jun-2026) is not subtracted separately: its cost is already in earnings, which is after interest. Retained capital reinforces subsidiaries' regulatory capital and Optum M&A (it does not accumulate free excess). Watch: whether the medical care ratio normalization holds without favorable reserve development, and the resolution of the Department of Justice case.

Today's elevated multiple is the price of growth: if the business grows, the entry point cheapens on its own going forward (the metric grows while EV stays roughly flat). The exit multiple at 3 years is higher than the terminal at 5 years —at 3 years there is more growth still ahead—, so the value curve shows whether value creation is concentrated in the early or the later years. The required return is applied to the base scenario.

They are valued separately, with their own rationale, and are not incorporated into the base or the verdict (they are excess return). When assigning them value — in Editmode —, the total with optionalities updates live, without moving the base.

The verdict, the base CAGR, and the margin of safety are always calculated on the base; optionalities do not alter them (with optionalities at $0 they do not move).

Each card fixes a required annual return and answers: if the business is worth $514 in 5 years, what is the maximum that can be paid today to obtain that return? Since it now trades at $379, the margin of safety is how much cheaper the market is than that maximum. The three thresholds: 4% covers inflation (the floor), 10% is the long-term average return, and 15% is the level of a great investment.

With a target price of $514 in 5 years plus $54 of dividends collected (the dividend adds to the return, not to the price) and a required return of 4.5% annually, the maximum to pay today is $460. Against the current market price ($379), the margin of safety is 17.6% (trades below the maximum → there is margin) and the total return at that price would be 8.8% annually.

• Normalized P/E, not trough. It is valued on P/E over normalized adjusted earnings (~$30 EPS by 2031, recovered from the 2025 trough), not the depressed figure. It is an insurer → equity-level P/E, not EV.
• The trailing figure misleads. The P/E on GAAP earnings carries charges and intangible amortization; on trailing-twelve-month adjusted earnings it trades at ~21×, and the multiple compresses toward ~13× as earnings recover.
• The DCF on normalized earnings. The DCF (at the risk-free rate, on normalized generation) gives a value above the price: recovered earnings support more than the current price.
• Margin of safety at the end. At ~$379 the base return (~+9%) comes from the earnings recovery + the dividend (~2.5%); the margin is moderate because part of the recovery is already visible and guided.
• The recovery is already visible. With the medical care ratio at 86.7% in 2Q26 and 2026 guidance raised twice, the 2025-trough bargain has narrowed: the base return depends on earnings continuing to normalize, not on a crisis valuation.
• Sensitivity — cycle vs reset. Value is highly sensitive to whether 2025 is a cycle (it normalizes) or a structural reset of Medicare Advantage funding; the DOJ is a tail risk that amplifies the sensitivity.

• ✓ ROIC exceeds the cost of capital (~10%)
• ✓ High incremental ROIC (compounding)
• ✓ CFROIC backs up the ROIC (109%, cash vs. accruals)
• ✓ Healthy balance sheet (low corporate debt)
• ✓ Durable competitive moat (multiple advantages)

• Strong, predictable cash flow. Cash flow is large but distorted by the timing of the CMS float (Medicare payments pull forward or lag depending on the period-end) — it is not capitalized raw; normalized earnings are the metric.
• Return on capital. Depressed in 2025 (ROE 12.8% vs 27% in 2023) by the trough; normalized, it returns well above the 10% bar. A business of historically high returns that took a hit.
• Creates economic value. Yes, normalized — scale and integration generate returns above the cost of capital; 2025 was a cyclical interruption, not a structural destruction (if the margin recovers).
• The trailing P/E trap. The P/E on trailing-twelve-month GAAP earnings carries intangible amortization and 2025's charges — misleading. It is valued on normalized adjusted earnings (~21× trailing-twelve-month adjusted), not the depressed level.
• The CMS float and the adjustments. Operating cash flow is inflated by the Medicare float; and the medical care ratio depends on prior-year reserve development — two adjustments to watch in earnings quality.
• Immaterial SBC. Stock-based compensation (~$1bn, ~0.2% of revenue) is immaterial → there is no SBC trap; P/E and owner-FCF converge.

Annual levels from the official filing (10-K); the % over each bar is the year-over-year (YoY) growth vs the prior year.

Insurance revenue (UnitedHealthcare) is premiums minus medical costs: the lever is the medical care ratio (MCR), which jumped to 89% in 2025 on the Medicare Advantage cost shock and is the key to the recovery (plans reprice). Optum earns from fees and higher-margin services: Optum Rx (pharmacy, $188bn of managed spend, +23% at the trough), Optum Health (value-based care, recovering), and Optum Insight (data, $31bn backlog). Operating cash flow is distorted by the timing of the CMS float — it is not capitalized raw.

The % are the annual (year-over-year) growth: each year —historical and projected— vs the prior one; the TTM (trailing 12m) vs the TTM of a year ago, to avoid overlapping windows. The historicals are exact figures from the official filings; the projected years come from the year-by-year model (the intermediate years without their own series are interpolated between the anchors). The projected columns (+1y…+5y) are 12-month windows counted from the TTM close (30-jun-2026): the projection starts from the most recently reported data, not the fiscal year. The projected base is realistic and unbiased — the risk discount is applied at the end, via the required return. The rationale for each metric is in the (i).

• Real, not nominal, growth. Revenue +12% is real (premiums + Optum), but earnings collapsed on the medical care ratio — earnings growth depends on margin recovery, not on the top line.
• Where the engine comes from. Optum (Rx +23%, services) grows through the cycle; insurance (UnitedHealthcare) recovers as it reprices. The normalized engine is Optum + margin recovery.
• Driven by the recovery. Five-year earnings growth comes from normalizing the medical care ratio (from 89% toward the mid-80s) and from Optum's scale — not from an accelerated top line.
• Realistic recovery. The base case projects adjusted earnings recovering from the trough ($16.35 EPS in 2025; 2026 guidance of $19.50-20.00) toward ~$30 by year five, decelerating the pace of recovery — not an instant return to the peak.
• Reinvestment runway. Wide: Optum (value-based care, pharmacy, data) has a secular runway, and scale funds M&A; the test is the return on capital of the acquisitions.
• Deliberate membership contraction. Medicare Advantage and Medicaid contract deliberately in 2026 (exiting unprofitable plans) — healthy for the margin, but it slows member growth in the short term.

• Relevant in 10 years / recurrence. Yes — health insurance and services are structural, recurring demand (annual premiums, Optum's multi-year contracts); healthcare spending grows with demographics.
• Market share / cost. First-order scale: $447.6bn of revenue in 2025, 48.5 million people in insurance and $188bn of pharmacy spend managed; scale gives a regulatory and cost barrier.
• Pricing power. Limited and regulated: Medicare Advantage premiums are set by the government (CMS), and 2025 showed that repricing lags cost when the trend surprises. Cyclical pricing power, not structural.
• Operating leverage. The insurance business's thin margin (~5% normalized) amplifies the cost shock: 3.6 points of medical care ratio erased 41% of the result. High leverage over a cost it does not fully control.
• Cost cycle / regulation. The Medicare Advantage cost-rate cycle and regulatory scrutiny (risk adjustment, pharmacy) are the threat; the moat does not neutralize them.
• Behavior in a recession. Defensive in demand (healthcare is not discretionary), but exposed to public funding policy (Medicare/Medicaid) and to eligibility redeterminations.

Not all debt is equal: only the structural needs refinancing; the rest is operational (self-liquidating).

Structural debt is what is exposed to the contraction phase of the cycle; operational debt (leases, matched funding) self-liquidates with the business.

• ✓Leverage (net debt / EBITDA)Net cash $0 bn
• !Interest coverage (EBIT / interest)5.6x
• –Liquidity (current ratio)no data
• ✓Cash quality (CFROIC vs ROIC)CFROIC backs 109% of ROIC
• ✓Value creation (ROIC − 10% bar)+6pp
• ✓Malinvestment test (capex vs incremental ROIC)Capex/D&A 0.8x — no over-investment
• –Float / working capitalNeutral WC
• ✓Dilution (SBC % of revenue + shares)SBC 0.2% of revenue

A traffic-light interpreted by the method (not generic): float (negative WC) adds up, capex is judged by incremental ROIC (malinvestment test), and a lender is not subjected to corporate solvency. The (i) shows the derivation of each number.

• Investment-grade balance sheet. Debt $73.3bn at Jun-2026 against $31.5bn of cash and short-term investments and $57.7bn of long-term investments (backing reserves and regulatory capital); debt to capital of 41.2% and trailing-twelve-month operating income 5.6 times interest expense. No solvency risk.
• Regulatory capital. The insurance subsidiaries maintain statutory capital; a good share of the cash/investments is not freely distributable — it backs medical reserves ($38.9bn of medical costs payable at Jun-2026).
• CMS float. Operating cash flow is distorted by the timing of Medicare payments (a swing of ~$10-16bn depending on the period-end) — a funding strength, but it is not capitalized as excess cash.
• Cash generation. Trailing-twelve-month operating cash flow ($27.0bn at Jun-2026, including the collection of a substantial government payment in 2Q26; ~$24bn guided for 2026) covers the dividend comfortably; capex is low (asset-light, $3.4bn) — the business generates cash even at the trough.
• Cycle, not solvency. The risk is margin (the Medicare Advantage cost cycle) and regulatory, not balance-sheet; the balance sheet passes through the trough with no solvency stress.

Who owns the shares — the alignment and whether there is a controlling shareholder.

• Capital allocation. Dividend prioritized (raised during the crisis), buybacks paused at the trough and resumed in 2Q26, Optum M&A. Discipline at the trough; the test is the return on reinvested capital.
• Alignment / skin in the game. Professional management (insiders <1%); Hemsley with a $60M three-year option (retention). Alignment through compensation structure, not through founder ownership.
• Capital return. Dividend maintained and raised during the crisis (strong signal); buybacks paused at the trough and resumed in 2Q26, with at least $5,000M guided for 2026.
• Succession / turnaround execution. Hemsley (a veteran, former CEO) returned to lead the turnaround after a chaotic year (CEO and CFO change). Two quarters of improvement and 2026 guidance raised in April and in July rebuild credibility; sustaining it without favorable reserve development remains the test.

• The P/E on trailing-twelve-month GAAP earnings is misleading: it carries the amortization of acquisition intangibles and 2025's restructuring and divestiture charges. On adjusted earnings it trades at ~21×, and earnings are still below their pre-crisis level (adjusted EPS $27.66 in 2024 versus $16.35 in 2025).
• The 2025 de-rating had a motivated-seller flavor: withdrawn guidance, a CEO and CFO change, and Department of Justice noise — which push out quality holders without the franchise being broken.
• Regulatory risk (Medicare Advantage audits, the Department of Justice lawsuit, pharmacy reform) is real but without crystallized charges: in the False Claims Act case, a Special Master recommended summary judgment for UnitedHealth, and the court has not yet ruled on the Department of Justice's request to reject that report.

The perception-reality gap was large at the 2025 trough, but with two guidance raises in 2026 the market has already priced in part of the recovery. What remains is a moderate discount on normalized earnings, conditional on 2025 being a cycle (it normalizes) rather than a structural reset — the question that decides the case.

The annual return (CAGR at 5 years) in each scenario, with the total period return below — the margin of safety made visual: upside range wide, downside range narrow.

Even in the bear scenario, the return holds at ~0%/year (+1% total): the margin of safety protects the downside. The bull (+13%/year, +87% total) exceeds it comfortably — a favorable asymmetry, with a narrow downside range and a wide upside range.

• Structural Medicare Advantage reset. If the cost shock and rate pressure (the 2027 Final Notice remains below cost trend) make a depressed margin the new base, earnings do not recover toward $27+ — the central disconfirmer.
• DOJ / regulatory. Medicare Advantage risk-adjustment (RADV) audits and the Department of Justice lawsuit under the False Claims Act: a Special Master recommended summary judgment for the company, the Department of Justice asked to reject that report, and the company cannot estimate the outcome — a tail risk over a margin engine.
• Optum Health loss-making. Value-based care swung to a loss in 2025 (−$278M) with a $623M reserve for expected 2026 losses; in 2Q26 it returned to a 5.1% operating margin, but the recovery still depends on managing medical cost.
• Pharmacy reform (PBM). Political and regulatory pressure on the pharmacy benefit managers (Optum Rx) could compress the margin of the portfolio's bright spot.
• Turnaround execution / confidence. After a chaotic year (CEO and CFO change, withdrawn guidance), management's credibility is being rebuilt with two quarters of improvement and two guidance raises; it is not yet a full-cycle test.

Each thinker's analytical framework applied to our data.

• Buffett / Graham Quality + margin of safety

  A wide moat and ROIC 16% above the 10% bar, but the margin is limited (+18%) → excellent business at a fair price.

• Peter Lynch Growth at a reasonable price (GARP)

  A stalwart growing 6% at a PEG of 3.6 → expensive for its growth.

• Joel Greenblatt Cheap and high-return (Magic Formula)

  Earnings yield 6% (EBIT/EV) + ROIC 16% → brushes the Magic Formula.

• Howard Marks Perception vs reality + cycle

  The price discounts -3% vs our 6%: perception is more pessimistic than reality, with an identified source of the discount.

• Seth Klarman Capital protection (bear scenario)

  Bear-scenario floor -3%/yr, bull-scenario ceiling +11%/yr over 5y → capital protected, asymmetry in your favor.

• Pat Dorsey Moat strength (Five Rules)

  A wide moat, stable; sources: efficient scale, switching costs, intangibles, cost advantage, network effects → passes the Five Rules.

• Aswath Damodaran Expectations implied by the price

  Justifying the price requires discounting -3%, within what we project (6%) — the story squares with the numbers.